A new randomized clinical trial found that psilocybin therapy reduced symptoms of depression in frontline clinicians affected by the COVID-19 pandemic, with effects lasting up to 6 months.
Results from a recent randomized controlled trial shows that cognitive-behavioral stress management (CBSM) significantly reduces anxiety, depression, and post-traumatic stress disorder in parents of...
In this COVID-19 roundup, researchers report on an increase in outpatient care following COVID-19 infection, cognition and memory impairment among those recovering from COVID-19, and more.
Patients with remitted major depressive disorder (MDD) appear to have more difficulty with the cognitive control of negative than positive information, according to study results published in the Journal of...
In a new study presented at CROI 2023, researchers examined how depression and anxiety in individuals with HIV impacts the risk of incident acute myocardial infarction in this patient population.
The American College of Physicians updated its recommendations on pharmacologic and nonpharmacologic treatment options for adults with major depressive disorder.
